Overview

• A chimeric inverted RNA interference molecule co-targets KRAS and MYC with tumor-directed delivery ligands, as detailed in the July 31 Journal of Clinical Investigation report
• Laboratory assays showed the dual-silencing construct reduced cancer cell viability up to forty-fold compared with separate siRNAs
• This design extends a prior KRAS G12V–specific delivery method to inactivate all KRAS mutations while concurrently silencing MYC
• Researchers are preparing preclinical in vivo evaluations in animal models to assess efficacy and safety ahead of clinical translation
• The flexible inverted siRNA architecture paves the way for expanded multi-gene targeting, including proof-of-concept efforts to silence three oncogenes simultaneously